



Investor Presentation

February 2026

A leader in AI-powered women's health solution spanning pregnancy to chronic care with a proprietary FDA-cleared device



Disclaimer

This presentation has been prepared by HeraMED Limited ('HMD') ABN 65 626 295 314.

All information contained in this presentation (including this notice) ('Information') is confidential. By receiving the forward-looking you are deemed to agree that you will hold the Information in strict confidence, and keep it secret, and not reproduce, disclose or distribute the Information to any third party or publish the Information for any purpose.

Except as required by law, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this presentation and to the extent permitted by law, you release HMD and their respective officers, employees, shareholders, advisers, agents and associates from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising forward-looking the reliance by you or any other person on anything contained in or omitted from this presentation.

Any forward looking statements included in the Information involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, HMD and their respective officers, employees, shareholders, advisors, agents or associates. Actual future events may vary materially from any forward looking statements and the assumptions on which those statements are based. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements.

No responsibility is accepted by HMD or any of their respective officers, employees, shareholders, advisers, agents or associates, nor any other person, for any of the Information or for any action taken by you on the basis of the Information. As a condition of accepting and receiving the Information you agree to release each of HMD and their respective officers, employees, shareholders, advisers, agents or associates and all other persons from any claim which you may otherwise be entitled to make in relation to the Information.

This presentation does not constitute investment, legal, taxation or other advice and the presentation does not take into account your investment objectives, financial situation nor particular needs. You are responsible for forming your own opinions and conclusions on such matters and should make your own independent assessment of the Information and any action taken on the basis of the Information.

The US Maternity Problem

The US has over 2×
the maternal mortality
rate of developed
nations¹

84%

of US pregnancy related
deaths are preventable³

10.4%

of US births are
preterm⁴

~60,000

U.S women face life-
threatening
complications annually²

1-in-4

US women receive
inadequate care

1. <https://www.commonwealthfund.org/publications/issue-briefs/2024/jun/insights-us-maternal-mortality-crisis-international-comparison>

2. <https://www.commonwealthfund.org/publications/issue-briefs/2021/oct/severe-maternal-morbidity-united-states-primer>

3. <https://www.aha.org/news/headline/2022-09-19-cdc-over-80-pregnancy-related-deaths-are-preventable>

4. <https://www.cdc.gov/nchs/fastats/births.htm>

HeraMED's Solution



Enterprise grade platform for Healthcare providers enabling continuous digital monitoring across maternity & women's health


- ✓ Remote monitoring of maternal and fetal health using connected medical devices
- ✓ Continuous clinical visibility by the healthcare provider
- ✓ Earlier risk detection and proactive intervention
- ✓ Scalable across pregnancy, postpartum, and broader women's health

HeraMED: Corporate Snapshot



HeraMED is a global medical data & technology company leading the digital transformation of women's care

12 Month Share Price Chart



ASX Code	ASX:HMD
Last Close (15 January 2026)	\$0.037
Shares on Issue (m)	1.11B
Market Capitalisation	~\$41m
Cash (31 December) + 3.2m Placement	~\$4.57m
Quarterly Burn	(\$0.69m)

Board of Directors

Tim Chapman	Chairman
Anoushka Gungadin	CEO & Managing Director
David Hinton	Non-Executive Director
Sharon Howell (US)	Non-Executive Director

Top 5 Shareholders

Investius PB Microcap A/C	3.83%
Foreshore Capital	3.30%
Ratdog Pty Ltd	2.97%
Always Holdings Pty Ltd	2.78%
Charlton WA Pty Ltd	2.59%

HeraMED Healthcare Veterans



HeraMED has transformed its teams to deliver upon its global commercialisation initiatives

Anoushka Gungadin
CEO & Managing Director



Seasoned exec with 20+ yr career spanning 5 continents

Cameron Jones
CFO & Co Secretary



Finance expertise in Biotech & life science companies

Jeff Garibaldi
Chief Growth Officer



35+ yrs in healthcare with vast experience in scaling
Two Exits \$700M Valuation

Mandy Khaira, MD, MPH
Chief Clinical Transformation Officer



CMO/CCTO with 24+ yrs in payer-provider & VBC

Vivek Krishnan
Chief Technology Officer



Seasoned healthcare exec, EMR/EHR & AI

Nicole Zappala
Head of Customer Success



Deep expertise in women's digital health solutions

Tim Chapman
Chairman of the Board



Seasoned exec with 20+ yr career in global investing

David Hinton
Non-Executive Director



Highly experienced CFO with 20+ yr exp in ASX listed companies

Sharon Richardson Howell, PhD MBA, FACHE, CPXP, MSc
NED & Advisory Board Chair



Fortune 25 Executive Leader, Community Health Advocate, & Investor excelling in Performance and Strategy

Dr. Adam Myers
Chair of Commercial Scientific Advisory Board



Nationally recognised U.S. healthcare leader

Cheryle Royle
Advisory Board



Experienced hospital CEO
Telstra Women's Award

Investment Highlights



HeraMED best-in-class digital health platform, HeraCARE is transforming maternity and women's care



HeraCARE: A Scalable Women's Health Platform

HeraCARE is a proprietary digital platform purpose-built for maternity and postpartum care, expanding across the life stages of women's health at scale.



Commercial Traction

Commercial customers and strategic partnerships with global healthcare and technology leaders support market access, credibility and scale-up.



Lean Operating Model

A capital-light, scalable operating structure designed to deliver commercial sustainability as the platform transitions to commercial rollout.



Clinically Validated

HeraCARE is validated in clinical settings, commercial pilots & healthcare partnerships, supported by an FDA-cleared fetal monitoring device & validated care pathways.



Large Under-Served Market

Women's healthcare is under-served and fragmented. HeraCARE addresses maternity today, with expansion across broader women's health and chronic care.



Highly experienced team

Growing US-based leadership team with deep experience in digital healthcare and a proven track record in commercial scale-up.

Challenges in Maternity Care

The maternity care in the US is worsening

Challenges



Century-old Model of care

Maternity care is delivered using an outdated model, with limited appointments & monitoring



Access/inequity of care

Where a woman lives (rural / maternity desert) materially impacts the quality & safety of her care.



Affordability of care

Maternity care is high-volume, high-cost and increasingly unsustainable for health systems.



Workforce shortage & burnout

Clinician shortages are reducing capacity and driving burnout across maternity services.

Outcomes

1 in 4 Women in US

DO NOT see a physician in the first trimester
DO NOT receive adequate care throughout pregnancy

Limited Visibility

Limited clinical visibility between appointments delays detection of complications

Maternal mortality

Maternal outcomes are getting worse, not better, even in developed healthcare systems.

US Maternity Crisis – Millions Left without Care

36% of the US is a maternity desert with no clinic: HeraMED is the solution to this critical issue




\$111B spent on maternity care annually¹



500+ hospitals closed maternity units since 2010²



22,000 shortage of OBGYNs by 2050³



Maternity Care Access

- Maternity Care Deserts (119)
- Low Access to Care (373)
- Moderate Access to Care (223)
- Access to Maternity Care (1427)



\$7.5B for hypertensive disorders annually⁴



\$18.1B for maternal mental health conditions⁴



\$4.8B for gestational diabetes complications⁴


1. <https://rockhealth.com/maternity-care-for-the-modern-era-our-investment-in-oula/>
2. <https://www.healthcare-brew.com/stories/2024/12/10/study-over-500-hospitals-closed-obstetrics-units-since-2010>

3. <https://www.motherjones.com/politics/2016/08/united-states-has-shortage-ob-gyns/>
4. Numbers represent US healthcare cost only, global cost are much higher www.marchofdimes.org/mission/the-economic-and-social-costs.aspx


Structural gaps in maternal care & monitoring

Limited provider access and lack of postpartum oversight drive preventable complications and mortality

Access to OB-GYNs & Midwives¹



Occurrence of Pregnancy related deaths¹



¹ . <https://www.commonwealthfund.org/publications/issue-briefs/2024/jun/insights-us-maternal-mortality-crisis-international-comparison>

HeraCARE

Mother's Perspective

1. Pregnancy Monitoring

- Remote vital signs monitoring & risk detection

2. Clinical Oversight


- Real-time visibility & health alerts

3. Postpartum Monitoring

- Post delivery monitoring & complication identification

4. Broader Women's Health Care

- Fertility → chronic care monitoring



HeraCARE

Healthcare Provider's Perspective

1. Continuous Remote Monitoring

- Real-time visibility
- Early identification of high-risk pregnancies

2. Decision Support

- Automated risk detection
- Evidence-based care plans

3. Seamless Integration

- Unified patient dashboard
- Simple integration

4. Scalable Care Delivery

- Increased patient volumes
- Enable proactive, preventative care



Delivering Efficient & Effective Care

From episodic appointments to continuous, clinically-guided maternity care



Task based care plans following clinical pathways

Low Risk High Risk

GDM



>50% fewer in-person visits
enabled by virtual care and ongoing telehealth engagement



Customised care plans
Personalised & clinically validated care plans designed based on health conditions



Detects complications early
such as pre-eclampsia risks, enabling for timely intervention



Ongoing postpartum support
Up to 12 months of monitoring, replacing the limited traditional single follow-up visit

HeraCARE - Outstanding Early Data



HeraMED addresses the challenges with a Next Gen, AI-Powered Solution Designed for Scale

Clinical Outcomes

Boosts clinician productivity by up to

46%

Identifies hypertension earlier by week

25

Face-to-face visits be replaced virtually

50%

Lowers patient no-shows to less than

10%

Postpartum readmissions approaching

0%

Increase in monitoring data vs SOC

200%

Dramatically cuts unscheduled specialist & ED visits

Patient Data

94%

Patient satisfaction result

96%

Patient adherence in pilot programs

+51 NPS

669 patients



HeraMED Revenue Generating Model



Multiple revenue streams per health system



**Recurring Platform
Revenue**

US\$50
per mum / per month

High-margin platform
subscription revenue that
scales with patient volumes



**Device &
Implementation**

Devices, deployment, integration, and configuration
funded by health systems at a margin



**Advanced Analytics
& Value Based Care
Savings**

(longer-term growth driver)

AI-driven analytics and population health insights

Shared savings and gain-share tied to improved
outcomes and efficiency

Key Figures: Market & HeraCARE Economics



HeraCARE improves outcomes, drives revenues, and delivers measurable savings and efficiencies

3.6m births
per year in the U.S.

1 in 4
Do not receive
adequate care²

1 in 175
Infant mortality
(21,000 p.a.)

10%
Preterm births

8.6%
Low birthweight¹

Indicative Hospital Economics ¹ (per pregnancy)	Low (US\$)	High (US\$)
Traditional Pregnancy Revenue ²	\$5,500	\$7,500
+ New HeraCARE Revenues	\$1,200	\$2,000
+ New HeraCARE Savings & Efficiencies	\$830	\$1,430
- HeraCARE Cost (US\$50 p/mum p/month)	\$300	\$900
= Return on Investment	2.2X	4.0X
= Total Economic Return	3.8X	6.8X
HeraCARE TAM	\$1.1Bn	\$3.2Bn
Additional Value to System	\$4.3Bn	\$8.6Bn

1. All figures are indicative only and subject to reimbursement and rates, which differ by US state and payer

2. Incremental values assume blended FFS and value-based participation.

Funding & Grants Supporting Digital Health

Government, federal, and health system funding accelerating adoption of remote monitoring and virtual care

Structural Funding Drivers

U.S. healthcare system under pressure, accelerating funding for scalable digital and remote care solutions

Women's health and maternity are priority investment areas, supported by federal and state funding programs

Major Funding Programs

CMS ACCESS Model

- funding remote monitoring and virtual care

Rural Health Transformation Program

- US\$50B to expand digital care access

LEAD (ACO) Model

- Supporting value-based care and proactive monitoring

Digital Health Initiatives

- Investing in interoperable and AI-enabled healthcare



HeraMED is positioned to leverage existing and future grant funding:

- ✓ Directly aligned with funded priorities including remote monitoring and preventative care
- ✓ Limited women's health platform alternatives
- ✓ Enables grant-supported deployment while improving outcomes and lowering costs
- ✓ Accelerates adoption and scalable rollout across women's health


Go to Market Strategy



Health Systems & Hospitals

Payers & Insurers

Public / Grant-Funded Health Programs



Commercialisation: Lee Health Rollout



Lee Health is a major US not-for-profit health system in Florida operating care hospitals, a children's hospital and a network of medical facilities supported by more than 1,100 physicians.

- Initial Clinical pilot of HeraCARE for 3-6 months
- Phase 2 scales up to 2,000 pregnancies
- Pathway to support commercialisation to Lee Health's 8,000 pregnancies delivered per year
- Lee Health pilot includes HeraBEAT devices to monitor pregnancies

~\$3B

Total health system
revenues for 2024

17,000

Total employees across
the organization

2M

Total patient contacts
each year

8,000

Pregnancies reported
each year

15+

Total hospitals and
outpatient centers

Commercialisation: Philips Partnership



Telcare Medical Supply LLC is a US-based subsidiary of Philips (NYSE:PHG), a global health technology leader operating established healthcare infrastructure and distribution capabilities to support large-scale clinical deployment.

- Commercial agreement to jointly offer a complete and integrated digital maternity care solution for U.S. hospitals and health systems
- Philips to provide its market-leading devices, logistics, and technical support & HeraMED to provide its proprietary HeraCARE platform
- The combination of Philips' device portfolio and infrastructure with HeraCARE will create a digital solution for maternity care at scale for U.S. hospitals and health systems

50+

Years leading maternal and fetal monitoring

7

Major pillars of offerings from ultrasound to smart solutions

20+

Years of enterprise remote patient monitoring

300+

Hospital Tele-ICU network footprint in the US

50+

States Virtual Care Mgmt. Clinical Coverage

Partnership: Garmin



Garmin (NYSE: GRMN) is a global leader in smartwatches and GPS-enabled products, with its Garmin Health division delivering digital health solutions powered by data from its wearable ecosystem.

- Strategic collaboration to integrate Garmin smartwatch data into HeraCARE clinical-grade maternity platform via the Garmin Health API
- Expands the range health data available to expectant mothers and healthcare providers, including heart rate, sleep quality and activity levels
- Joint collaborate marketing efforts to promote integrated solutions
- Collaboration includes exploration of women's health research opportunities

30+

Years pioneering fitness and wellness technology

20+

Wearables with advanced health and biometric sensors

10+

Years of delivering Garmin Health enterprise solutions

70+

Countries with Garmin Health deployments

24/7

Continuous monitoring for women's health

Digital Women's Health Platforms

Most providers focus on specific components of women's health

HeraMED delivers personalised care with AI-enabled intelligence across women's health life stages into a single scalable platform



	Level 1	Level 2	Level 3	Level 4
	Remote Patient Monitoring	Maternity-Specific Solutions	Digital Women's Health Platform	AI-Enabled Enterprise Women's Health Platform
Key Providers				
Vitals Monitoring	✓	✓	✓	✓
Pregnancy Monitoring	✗	✓	✓	✓
Postpartum Monitoring	✗	△	✓	✓
Personalised Care Plans	✗	△	✓	✓
Regulated Medical Device	△	✓	✗	✓
Reimbursement Enabled	✓	✓	△	✓
AI Clinical Decision Support	✗	✗	△	✓
Broader women's health monitoring capabilities	✗	✗	△	✓


✓ = Core capability △ = Limited or partial ✗ = Not present

The Future

HeraMED aims to deliver the worlds first end-to-end women's health management platform




Fertility to Chronic Care Management



HeraMED Development Timeline



Building momentum: validated platform, strengthened leadership, and early commercial traction



2026 Pivotal Milestones

0-6 Months

Prepare for Commercial Scale

Converting Pilots into Hospital Deployments

- **Progress hospital commercial model** in partnership with Philips
- **Advance Lee Health from pilot to Phase 2**, expanding patient volumes toward ~2,000 pregnancies
- **Scale patient onboarding and monitored pregnancies** to support initial revenue-generating deployments
- **Beta Launch initial AI-enabled clinical support** features into production
- **Leverage Commercial Scientific Advisory Board** to support health system adoption and scale
- **Activate Australian commercial rollout** following TGA Class IIb approval, targeting private clinics

6-12 Months

Scale Commercial Deployment

Scaling health system adoption

- **Expand Lee Health into Phase 2**, increasing patient volumes
- **Deploy at least one US hospital** under commercial model under Philips partnership.
- **Secure 1–2 additional U.S. commercial customers**
- **Publish clinical and health economics data** supporting adoption and reimbursement
- **Progress AI-driven maternity care model** toward broader, system-wide use
- **Leverage U.S. government and health system funding programs** to support scaled deployment and AI development
- **Extend HeraCARE** into a new women's health use case beyond maternity



HERA-MED.COM

Anoushka Gungadin - CEO & Managing Director
anoushka@hera-med.com